Neoplastic B-cell growth is impaired by HLA-G/ILT2 interaction
| Autor: | Nathalie Rouas-Freiss, Catherine Menier, Guitta Maki, Abderrahim Naji, Edgardo D. Carosella |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Cancer Research
Lymphoma B-Cell medicine.drug_class Lymphoproliferative disorders Monoclonal antibody Leukocyte Immunoglobulin-like Receptor B1 Antigens CD Cell Line Tumor hemic and lymphatic diseases HLA-G Leukemia B-Cell medicine Humans Receptors Immunologic Multiple myeloma B cell Cell Proliferation HLA-G Antigens B-Lymphocytes business.industry Hematology medicine.disease Lymphoma medicine.anatomical_structure Oncology Apoptosis Immunology Rituximab Multiple Myeloma business Protein Binding medicine.drug |
| Zdroj: | Leukemia. 26:1889-1892 |
| ISSN: | 1476-5551 0887-6924 |
| Popis: | Deregulation of B-cell proliferation may induce malignant growth causing various lymphoproliferative disorders including the most prevalent hematological malignancies in adult, namely lymphoma, multiple myeloma (MM) and B-cell chronic lymphocytic leukemia.1 Inducing depletion through an apoptotic pathway or inhibiting B-cell proliferation and differentiation constitutes a rational approach to cure B-cell-mediated disorders. One such modality used recently in B-cell malignancies is rituximab, a B-cell-depleting monoclonal antibody against CD20.2 Nevertheless, efforts to identify novel therapeutic targets remain essential. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|